These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 15153345)

  • 1. [Inhibitors of fusion: a new alternative in the treatment of HIV infection].
    Roca Villanueva B
    Med Clin (Barc); 2004 May; 122(17):659-60. PubMed ID: 15153345
    [No Abstract]   [Full Text] [Related]  

  • 2. [The current progress in the development of HIV-1 fusion inhibitors].
    Shi WG; Jia QY; Liu KL
    Yao Xue Xue Bao; 2010 Feb; 45(2):184-93. PubMed ID: 21351428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enfuvirtide antiviral activity despite rebound viremia and resistance mutations: fitness tampering or a case of persistent braking on entering?
    Morse C; Maldarelli F
    J Infect Dis; 2007 Feb; 195(3):318-21. PubMed ID: 17205468
    [No Abstract]   [Full Text] [Related]  

  • 4. Enfuvirtide: antiretroviral class 4, drug 1.
    Asboe D
    HIV Clin Trials; 2004; 5(1):1-6. PubMed ID: 15002081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New drugs show promise in attacking HIV.
    Dent Today; 2002 Dec; 21(12):30. PubMed ID: 12572158
    [No Abstract]   [Full Text] [Related]  

  • 6. Enfuvirtide for prophylaxis against HIV Infection.
    Ferranti S; Menichetti F
    N Engl J Med; 2003 Aug; 349(8):815. PubMed ID: 12930939
    [No Abstract]   [Full Text] [Related]  

  • 7. Enfuvirtide.
    Lalezari JP; Luber AD
    Drugs Today (Barc); 2004 Mar; 40(3):259-69. PubMed ID: 15148534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to enfuvirtide, the first HIV fusion inhibitor.
    Greenberg ML; Cammack N
    J Antimicrob Chemother; 2004 Aug; 54(2):333-40. PubMed ID: 15231762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV entry inhibitors: progress in development and application.
    Lai WH; Huang L; Chen CH
    Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Full fusion competence rescue of the enfuvirtide resistant HIV-1 gp41 genotype (43D) by a prevalent polymorphism (137K).
    Tolstrup M; Selzer-Plön J; Laursen AL; Bertelsen L; Gerstoft J; Duch M; Pedersen FS; Ostergaard L
    AIDS; 2007 Feb; 21(4):519-21. PubMed ID: 17301572
    [No Abstract]   [Full Text] [Related]  

  • 11. Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors.
    Pan C; Lu H; Qi Z; Jiang S
    AIDS; 2009 Mar; 23(5):639-41. PubMed ID: 19242316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development.
    Cooper DA; Lange JM
    Lancet Infect Dis; 2004 Jul; 4(7):426-36. PubMed ID: 15219553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a novel fusion inhibitor against T-20-resistant HIV-1.
    Oishi S; Ito S; Nishikawa H; Tanaka M; Ohno H; Otaka A; Izumi K; Kodama E; Matsuoka M; Fujii N
    Adv Exp Med Biol; 2009; 611():389-91. PubMed ID: 19400237
    [No Abstract]   [Full Text] [Related]  

  • 14. Discontinuation of the clinical development of fusion inhibitor T-1249.
    Martin-Carbonero L
    AIDS Rev; 2004; 6(1):61. PubMed ID: 15168742
    [No Abstract]   [Full Text] [Related]  

  • 15. [Enfuvirtide, mechanism of action and pharmacological properties].
    Kapić E; Becić F; Zvizdić S
    Med Arh; 2005; 59(5):313-6. PubMed ID: 16134757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy.
    Poveda E; Rodés B; Lebel-Binay S; Faudon JL; Jimenez V; Soriano V
    J Clin Virol; 2005 Dec; 34(4):295-301. PubMed ID: 16286053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Enfuvirtide. Two injections per day for HIV].
    Taéron C
    Rev Infirm; 2004 Oct; (104):35-6. PubMed ID: 15581312
    [No Abstract]   [Full Text] [Related]  

  • 18. Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen.
    Deeks SG; Lu J; Hoh R; Neilands TB; Beatty G; Huang W; Liegler T; Hunt P; Martin JN; Kuritzkes DR
    J Infect Dis; 2007 Feb; 195(3):387-91. PubMed ID: 17205477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV entry and fusion inhibitors.
    Chantry D
    Expert Opin Emerg Drugs; 2004 May; 9(1):1-7. PubMed ID: 15155132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A synthetic C34 trimer of HIV-1 gp41 shows significant increase in inhibition potency.
    Nomura W; Hashimoto C; Ohya A; Miyauchi K; Urano E; Tanaka T; Narumi T; Nakahara T; Komano JA; Yamamoto N; Tamamura H
    ChemMedChem; 2012 Feb; 7(2):205-8. PubMed ID: 22247043
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.